Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of EUR-1008 in CP Patients with EPI
NCT00788593Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Jan 2008
- Primary completion
- Mar 2009
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of pancreatin in exocrine pancreatic insufficiency (EPI), sponsored by Forest Laboratories. Started Jan 2008; status: completed.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT00788593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00788593.